Ningxia Zhongke Biotech announced that it recently received a notice from the manager that its account has received all restructuring investment payments from all restructuring investors, totaling 1,241 billion yuan. Earlier, investors and financial investors in industries such as Hunan Alcohol Investment signed separate pre-restructuring investment agreements with the company and temporary managers. However, there is a risk that the company will terminate its listing. If it does not execute or cannot execute the restructuring plan, it will be declared bankrupt and liquidated, and the stock will face termination of listing; in addition, the investment agreement may also be terminated or terminated. If its subsidiaries Zhongke New Materials and Hengli Guomao do not implement the restructuring plan, they are also at risk of being declared bankrupt.

Ningxia Zhongke Biotech announced that it recently received a notice from the manager that its account has received all restructuring investment payments from all restructuring investors, totaling 1,241 billion yuan. Earlier, investors and financial investors in industries such as Hunan Alcohol Investment signed separate pre-restructuring investment agreements with the company and temporary managers. However, there is a risk that the company will terminate its listing. If it does not execute or cannot execute the restructuring plan, it will be declared bankrupt and liquidated, and the stock will face termination of listing; in addition, the investment agreement may also be terminated or terminated. If its subsidiaries Zhongke New Materials and Hengli Guomao do not implement the restructuring plan, they are also at risk of being declared bankrupt.